The World Health Organization (WHO) has added tocilizumab, a monoclonal antibody, to its list of prequalified treatments for COVID-19.
To date, six COVID-19 treatments have been prequalified by WHO, including the three presentations (three vials, each with a different quantity) of tocilizumab.
The three prequalified products are manufactured by Roche, but WHO said, “the listings should pave the way for more companies coming forward to seek WHO prequalification, thereby increasing the number of quality-assured products and creating competition leading to potentially lower prices. The prequalification of these products will also facilitate low- and middle-income countries’ authorization of them as COVID treatments.”
Tocilizumab is a monoclonal antibody that inhibits the Interleukin-6 (IL-6) receptor. Interleukin-6 induces an inflammatory response and is found in high levels in patients critically ill with COVID-19.
So far, the product has been authorized mostly for the treatment of arthritis in about 120 countries worldwide.
Tocilizumab given intravenously has been shown in clinical studies to reduce death in certain patients with COVID-19 who are severely ill, are rapidly deteriorating and have increasing oxygen needs, and who have a significant inflammatory response. In the largest clinical trial (RECOVERY), tocilizumab also reduced patients’ time in hospital.
WHO recommends tocilizumab only for patients diagnosed with severe or critical COVID-19, and it should only be administered by a healthcare worker in a monitored clinical setting.
“The patent for tocilizumab has expired for most of its uses, which means there should be no intellectual property barriers for this particular IL-6 blocker. However, there is low global availability of quality-assured biosimilars of the product,” the WHO said. However, “tocilizumab is expensive and in short supply globally. Originator company prices paid in lower-income markets are high — reportedly around USD 500-600 per single dose. With demand surging, and more manufacturers entering the market, prices could come down.” the WHO added.
